

Original Research Article

ANALYSIS OF CARDIOPULMONARY STATUS IN RENAL TRANSPLANT RECIPIENTS – A RETROSPECTIVE STUDY

D. Pavithran¹, Geetha Ravi²

¹Postgraduate, Department of Anaesthesiology, Dhanalakshmi Srinivasan, Medical College and Hospital, India. ²Associate Professor, Department of Anaesthesiology, Dhanalakshmi Srinivasan, Medical College and Hospital, India.

 Received
 : 05/11/2023

 Received in revised form:
 : 22/12/2023

 Accepted
 : 08/01/2024

Corresponding Author: Dr. Geetha Ravi

Associate Professor, Department of Anaesthesiology, Dhanalakshmi Srinivasan, Medical College and Hospital, India.

Email: geetha.adiart@gmail.com

DOI: 10.5530/ijmedph.2024.1.41

Source of Support: Nil, Conflict of Interest: None declared

Int J Med Pub Health 2024; 14 (1); 211-215

ABSTRACT

Background: Uremic syndrome is Known to invariably involve all systems in the body. The cardiopulmonary status of patient in end stage renal disease need meticulous evaluation and contemplation for perioperative management. safe induction and planning of elective ventilation depends on cardiac function, anemia & pulmonary hypertension along with urine output on the table following vascular anastomosis. This study analysis well defined parameters to formulate recommendation on concrete observation.

Materials and Methods: Study: Retrospective, Study period: April 2022 - June 2023, Study population: all patient who presented for PAC for renal transplantation. All patient were on antihypertensive and on hemodialysis, Sample size: 40 patients, All patient has undergone renal transplantation with successfull outcome under general anaesthesia, Patient data: age/sex/pulse BP

Parameters analysed: EF /RWMA/ Hb. /RVSP, the ejection fraction indicates LV systolic function, RWMA about LV dilatation and hypokinesia, Anemia the severity is multifactorial and RVSP indicate pulmonary hypertension, **Aim:** To analyse data documented data for cardiopulmonary status in renal transplant recipients, **Objective:** • Predict and anticipate specific problems for intraoperative choice of drugs. • Anticipate and plan for elective post-operative ventilation. • Recommendation for further intensive and extended monitoring. **Results:** • Right ventricle systolic pressure which indicates pulmonary

hypertension correlates significantly with hemoglobin with p value of 0.038

- Duration of renal disease categorically correlated with anemia (p 0.9) this parameters may have limitations as duration is subjective

• Ejection fraction which denotes LV systolic function correlated with duration of hemodialysis (p 0.5)

• 5 patients had global hypokinesia of LV along with anemia and moderate PHT

Conclusion: Untreated or Neglected duration of hypertension or protenuria was associated with severe anemia all the effect of end stage disease is due to vascular remodeling & endothelial dysfunction. This is indicated by severe anemia often associated with moderate to severe pulmonary hypertension. Duration of dialysis is related to cardiac dysfunction due to fluid and circulatory volume handling altered by kidney.

Keywords: Renal transplant recipients, RVSP, EF.

INTRODUCTION

Hypertension and Type 2 Diabetes Mellitus are the • Renal transplantation is the most successful of all the organ transplant procedures • End-stage renal disease revolves around fluid Handling and load on Cardiovascular and pulmonary system

- cardiopulmonary status of the patient in endstage renal disease need meticulous evaluation and contemplation for perioperative management
- Renal replacement therapy further alters the hemodynamics, challenging every stage of conduct of anesthesia
- The outcome depends on the urine output and morbidity and mortality depends on cardiopulmonary status of the recipient
- This study analyses the Cardiopulmonary status, evaluation by simple routine parameters and correlation of the indicators

Aim

• To analyze the EF /RWMA/ Hb. /RVSP (right ventricle systolic pressure) from PAC data in renal transplant recipients

Objective

- Predict and anticipate specific problems such as perioperative pulmonary edema and hypoxia
- Anticipate and plan for elective post-operative ventilation
- Recommendation for further intensive and extended monitoring

MATERIAL AND METHODS

Study: retrospective

```
Study period: April 2022 to June 2023
```

Study population: all patients with ESRD who presented for PAC for renal transplantation.

All patient were on antihypertensive and on hemodialysis

Sample size: 40 patients


All patient has undergone renal transplantation with successful outcomes


Parameters analyzed: EF /RWMA/ Hb. /RVSP


The ejection fraction indicates LV systolic function, RWMA about LV dilatation and hypokinesia The causes of Anemia in ESRD are multifactorial and RVSP indicate pulmonary hypertensiony.

RESULTS

- Right ventricle systolic pressure which indicates pulmonary hypertension correlates significantly with hemoglobin with p value of 0.038
- Duration of renal disease categorically correlated with anemia (p 0.9) this parameter may have limitations as duration is subjective
- Ejection fraction which denotes LV systolic function correlated with duration of hemodialysis (p 0.5)
- 5 patients had global hypokinesia of LV along with anemia and moderate PHT














Figure 3: Duration of renal disease and hb

Statistic	0.03
P - value	0.94




Figure 4: EF vs Duration of hemodialysis

Statistic	0.13
P - value	0.51

S.no	PR	BP	EF %	RWMA	Hb%
1	84	170/100	62%		15.9
2	102	140/80	63		5.7
3	76	150/100	54		9.1
4	80	190/110	40		7.6
5	90	130/80	60		7.1
6	96	170/90	55		12.1
7	86	160/80	63		10.6
8	88	140/80	55		8.8
9	86	150/100	60		8.1
10	86	90/70	62		14
11	90	170/90	60		7.5
12	80	200/100	46		8
13	86	160/80	58		7.1
14	80	140/90	62		12.2
15	60	200/120	55		6.7
16	76	120/90	63		11.6
17	90	140/80	65		10
18	120	150/90	40		6.7
19	90	130/50	42		6.8
20	76	100/60	47		6
21	80	150/100	68		8.0
22	90	150/100	44	Global hypokinesia LV	8.4
23	70	200/100	40	+	12.1
24	80	200/100	62		8.3
25	92	150/100	55		7.4
26	76	130/70	50		11.0
27	86	120/70	55		7.5
28	80	160/90	58		6.0
29	82	160/90	55		10.4
30	120	150/90	60		8.5
31	86	140100	55		4.9
32	80	17080	62		11.0
33	88	13090	34		10.8
34	96	16094	38	+	5.9
35	70	220140	52	+	8.1
36	90	16080	50	+	7.9
37	80	14090	38		9.8
38	90	12070	60		7.6
39	84	13080	60		8.3
40	76	16060	62	1	7.5

Table 2: Pulmonary st	atus			
S.no	RR	Spo2	RVSP	Hb%
1	22	98	32	15.9
2	20	96	44	5.7
3	18	99	24	9.1
4	26	95	55	7.6
5	16	98	15	7.1
6	18	97	26	12.1
7	20	99	37	10.6

$\begin{tabular}{ c c c c c c c c c c c c c c c c c c c$	
$\begin{tabular}{ c c c c c c c c c c c c c c c c c c c$	
$\begin{tabular}{ c c c c c c c c c c c c c c c c c c c$	-
$\begin{array}{ c c c c c c c c c c c c c c c c c c c$	-
$\begin{array}{ c c c c c c c c c c c c c c c c c c c$	
$\begin{tabular}{ c c c c c c c c c c c c c c c c c c c$	
$\begin{tabular}{ c c c c c c c c c c c c c c c c c c c$	
$\begin{array}{ c c c c c c c c c c c c c c c c c c c$	
$\begin{tabular}{ c c c c c c c c c c c c c c c c c c c$	
$\begin{tabular}{ c c c c c c c c c c c c c c c c c c c$	
$\begin{tabular}{ c c c c c c c c c c c c c c c c c c c$	
$\begin{array}{ c c c c c c c c c c c c c c c c c c c$	
$\begin{array}{ c c c c c c c c c c c c c c c c c c c$	
$\begin{array}{ c c c c c c c c c c c c c c c c c c c$	
$\begin{tabular}{ c c c c c c c c c c c c c c c c c c c$	
$\begin{array}{ c c c c c c c c c c c c c c c c c c c$	
$\begin{array}{ c c c c c c c c c c c c c c c c c c c$	i
$\begin{tabular}{ c c c c c c c c c c c c c c c c c c c$	
$\begin{array}{ c c c c c c c c c c c c c c c c c c c$	
$\begin{array}{ c c c c c c c c c c c c c c c c c c c$	
$\begin{array}{ c c c c c c c c c c c c c c c c c c c$	
$\begin{array}{ c c c c c c c c c c c c c c c c c c c$	
$ \begin{array}{ c c c c c c c c c c c c c c c c c c c$	ŧ
$ \begin{array}{ c c c c c c c c c c c c c c c c c c c$	
33 18 100 40 10.8 34 24 96 15 5.9 35 18 99 32 8.1	
34 24 96 15 5.9 35 18 99 32 8.1	
35 18 99 32 8.1	3
35 18 99 32 8.1	
<u>36</u> 20 99 51 7.9	
37 18 100 40 9.8	
38 18 99 42 7.6	
<u>39</u> 18 99 34 8.3	
40 22 98 40 7.5	

DISCUSSION

The incidence of pulmonary hypertension is high in patients with ESRD.

The gold standard of pulmonary hypertension evaluation is right heart catheterization- an invasive procedure with risks.

Echocardiography provides measurement of right ventricle systolic pressure based on estimated flow through tricuspid vale.

Adaptation of cvs in ESRD

ESRD ---> Increased vascular resistance and increased circulating fluid volume








Figure 6: Adaptation of CVS in ESRD

Causes of anemia in ESRD

- Vascular and renal endothelium shares the same origin
- Uremia causes endothelial dysfunction and vascular remodeling
- Platelet dysfunction and splenic sequestration
- Uremic gastritis and occult gastric bleed
- Immune mechanism
- Rate of hemolysis is 2-3 times due to uremic toxins
- Erythropoietic response of bone marrow to anemia fails
- Increased oxidative stress due to uremic toxins
- Increases flow from AV fistula causes vascular calcification
- Heparin-induced bleeding due to usage on hemodialysis

Prevalence %
9-39.3
18.5-68.5
0-42

Table 4:

Factors affecting cardiopulmonary status in ESRD	
Anemia	
Pulmonary hypertension	
Ejection fraction	
Right ventricle systolic pressure	

Table 5:

Pulmonary pressure	RVSP mm/hg
Normal	<35
Mild PHT	35-45
Moderate	45-60
Severe	>60

CONCLUSION

- With endothelial Dysfunction has common Denominator severity of anemia (Hb<9gm) associated with pulmonary hypertension.
- hence correlation of anemia might help in reducing pulmonary pressures apart from Pharmacological management.

REFERENCES

- 1. Pulmonary hypertension and postoperative outcome in renal transplant: A retrospective analysis of 170 patients Vipin Kumar Goyal, Sohan Lal Solanki1, Birbal Baj
- Hoeper MM, Bogaard HJ, Condliffe R, Frantz R, Khanna D, Kurzyna M, et al. Definitions and diagnosis of pulmonary hypertension. J Am Coll Cardiol 2013;62: D42-50.
- Chemla D, Humbert M, Sitbon O, Montani D, Hervé P. Systolic and mean pulmonary artery pressures: Are they interchangeable in patients with pulmonary hypertension? Chest 2015; 147:943-50.
- Burhan Dost, Muzeyyen Beldagli, Cengiz Kaya, Yasemin Burcu Ustun, Sezgin Bilgin, Ersin Koksal, Yakup Bostancı. Anesthetic Management of Patients Undergoing Renal Transplantation: A Review of a Two-year Experience. Signa Vitae. 2021. 17(1):95-100
- Yigla M, Nakhoul F, Sabag A, Tov N, Gorevich B, Abassi Z, et al. Pulmonary hypertension in patients with end-stage renal disease. Chest. 2003; 123:1577–82. [PubMed] [Google Scholar]
- Paneni F, Gregori M, Ciavarella GM, Sciarretta S, De Biase L, Marino L, et al. Right ventricular dysfunction in patients with end-stage renal disease. Am J Nephrol. 2010; 32:432–8.

- Bozbas SS, Akcay S, Altin C, Bozbas H, Karacaglar E, Kanyilmaz S, et al. Pulmonary hypertension in patients with end-stage renal disease undergoing renal transplantation. Transplant Proc. 2009; 41:2753–6.
- Abedini M, Sadeghi M, Naini AE, Atapour A, Golshahi J. Pulmonary hypertension among patients on dialysis and kidney transplant recipients. Ren Fail. 2013; 35:560–5.
- Agarwal R. Prevalence, determinants and prognosis of pulmonary hypertension among hemodialysis patients. Nephrol Dial Transplant. 2012; 27:3908–14.
- Kaw R, Pasupuleti V, Deshpande A, Hamieh T, Walker E, Minai OA, et al. Pulmonary hypertension: An important predictor of outcomes in patients undergoing non-cardiac surgery. Respir Med. 2011; 105:619–24.
- Ramakrishna G, Sprung J, Ravi BS, Chandrasekaran K, McGoon MD. Impact of pulmonary hypertension on the outcomes of noncardiac surgery: Predictors of perioperative morbidity and mortality. J Am Coll Cardiol. 2005; 45:1691– 9.
- Schilling M, Holzinger F, Friess H, Seiler C, Büchler MW. Pathogenesis of delayed kidney graft function: Role of endothelin-1, thromboxane B2, and leukotriene B4. Transplant Proc. 1996; 28:304–5.
- Zlotnick DM, Axelrod DA, Chobanian MC, Friedman S, Brown J, Catherwood E, et al. Non-invasive detection of pulmonary hypertension prior to renal transplantation is a predictor of increased risk for early graft dysfunction. Nephrol Dial Transplant. 2010; 25:3090–6.
- Beigi AA, Sadeghi AM, Khosravi AR, Karami M, Masoudpour H. Effects of the arteriovenous fistula on pulmonary artery pressure and cardiac output in patients with chronic renal failure. J Vasc Access. 2009; 10:160–6.
- Unal A, Tasdemir K, Oymak S, Duran M, Kocyigit I, Oguz F, et al. The long-term effects of arteriovenous fistula creation on the development of pulmonary hypertension in hemodialysis patients. Hemodial Int. 2010; 14:398–402.